Acute bronchiolitis

disease
On this page

Also known as acute capillary bronchiolitisCapillary pneumonia

Summary

Acute bronchiolitis (MONDO:0020680) is a disease and 23 clinical trials. Top therapeutic interventions include montelukast, sodium chloride, and albuterol. A subtype of bronchiolitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 23

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameacute bronchiolitis
Mondo IDMONDO:0020680
ICD-10-CMJ21
ICD-111310075986
NCITC39659
SNOMED CT5505005
UMLSC0001311
MedGen113
Is cancer (heuristic)no

Also known as: acute bronchiolitis · acute capillary bronchiolitis · Capillary pneumonia

Disease family

This is a subtype of bronchiolitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorderlower respiratory tract disorderlung disorderbronchiolitisacute bronchiolitis

Related subtypes (5): bronchiolitis obliterans syndrome, toxic bronchiolitis, respiratory syncytial virus bronchiolitis, postinfectious bronchiolitis obliterans, Mac-Leod-Swyer-James-Syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 23.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified13
PHASE45
PHASE33
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01660867PHASE4WITHDRAWNNebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department
NCT01871857PHASE4COMPLETED7% Hypertonic Saline for Acute Bronchiolitis
NCT03880903PHASE4UNKNOWNHypertonic Saline Inhalation in Acute Bronchiolitis
NCT04613180PHASE4UNKNOWNEvaluation of the Effectiveness of Montelukast in Children With Recurrent Obstructive Bronchitis
NCT06441162PHASE4TERMINATEDEfficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis
NCT01469845PHASE3COMPLETEDThe SABRE Trial of Hypertonic Saline in Acute Bronchiolitis
NCT01875757PHASE3COMPLETEDEffect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life
NCT03171142PHASE3COMPLETEDEffect of Heliox on RSV Bronchiolitis
NCT06558461PHASE2/PHASE3COMPLETEDNebulised 3% Hypertonic Saline in Infants With Acute Bronchiolitis
NCT06139029EARLY_PHASE1COMPLETEDComparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis
NCT06321133Not specifiedRECRUITINGHigh Flow Nasal Cannula Weaning in Acute Bronchiolitis
NCT06636955Not specifiedRECRUITINGViral Epidemiology of Bronchiolitis After Nirsevimab Implementation and Respiratory Evolution in Infants
NCT07138625Not specifiedNOT_YET_RECRUITINGNebulized 3% Hypertonic Saline Versus Normal Saline in Managing Children With Acute Bronchiolitis: A Randomized Controlled Trial
NCT07359287Not specifiedRECRUITINGImpact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
NCT07505420Not specifiedNOT_YET_RECRUITINGRisk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital
NCT02029040Not specifiedCOMPLETEDNebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis
NCT02093715Not specifiedUNKNOWNFeNO and Cytokines in Respiratory Syncytial Virus (RSV) and Non RSV Bronchiolitis in Relation to Future Asthma
NCT02962505Not specifiedCOMPLETEDContinuous Regional Analysis Device for Neonate Lung
NCT02984046Not specifiedUNKNOWNAcute Bronchiolitis and Severity Markers: Interest in Protein CC16
NCT03753802Not specifiedUNKNOWNEvaluation of the Effects of Respiratory Physiotherapy in Infants With Moderate Acute Bronchiolitis
NCT03915197Not specifiedUNKNOWNAcute Bronchiolitis in Infants and Allergic Asthma
NCT04245202Not specifiedCOMPLETEDComparison of High Flow Nasal Cannula and Standard Face Mask Oxygen Therapy in Children With Bronchiolitis
NCT04748159Not specifiedCOMPLETEDEffects of Prone Positioning on Vital Parameters in Infants With Acute Bronchiolitis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
MONTELUKAST43
SODIUM CHLORIDE43
ALBUTEROL41
BETAMETHASONE41
DEXAMETHASONE41
EPINEPHRINE41
RACEPINEPHRINE21
CHEMBL543030501
CHEMBL123091401
AIR, MEDICAL-11